Anlon Healthcare is a research-intensive manufacturing unit of Pharmaceutical Bulk Drugs and intermediates. Based in Rajkot, they've earned a global recognition for manufacturing products that adhere to the highest standards of quality. Their products comply with the regulatory requirements of leading health authorities such as FDA, PMDA, KFDA, cGMP, WHO-GMP. With exceptional R&D capabilities, advanced API manufacturing facilities, global regulatory accreditations, a strong product pipeline and speed-to-market competencies, ANLON is an ideal API partner.

The company is led by strong Promoters, PUNITKUMAR R. RASADIA, who has over 11 years of experience in the pharmaceutical industry, and he has a deep understanding of sourcing and supplying of specialty chemicals, intermediates, API, bulk drugs and other pharmaceutical products, MEET ATULKUMAR VACHHANI has over 11 years of experience in pharmaceutical industry, he oversees the Company’s administration, strategy, finance and sales functions and MAMATA PUNITKUMAR RASADIA.

The Revenues from operations for the Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 12,045.51 Lakh, ₹ 6,669.19 Lakh and ₹ 11,312.00 Lakh. The EBITDA for the Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 3,237.73 Lakh, ₹ 1,556.93 Lakh and ₹ 1,265.74 Lakh. The Profit after Tax for the Fiscals ended on Mar 31, 2025, 2024 and 2023 were were ₹ 2,051.79 Lakh, ₹ 965.71 Lakh and ₹ 582.00 Lakh respectively. This indicates a steady growth in financial performance.

The Company Key Performance Indicates the pre-issue EPS of ₹ 6.38 and post-issue EPS of ₹ 3.86 for FY24. The pre-issue P/E ratio is 14.26x, while the post-issue P/E ratio is 23.57x against the Industry P/E ratio is 42x. The company's ROCE for FY24 is 21.93%, ROE for FY24 is 67.99% and RoNW is 25.51%. These metrics suggest that the IPO is fairly priced.

The Grey Market Premium (GMP) of Anlon Healthcare showing listing gains of 0.00 %.Given the company's financial performance and the valuation of the IPO, we recommend Investors to Avoid to the Anlon Healthcare Limited IPO for Listing gain.

Disclaimer: The information provided in this IPO review is for educational and informational purposes only and should not be construed as financial advice or an offer to buy or sell securities. The review must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. The content is based on publicly available information and market perceptions as of the date of publication and is subject to change. Neither the author nor the website is responsible for any losses or damages arising from the use of this information. 1.“Registration granted by SEBI, membership of a SEBI recognized supervisory body (if any) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.” 2. “Investment in securities market are subject to market risks. Read all the related documents carefully before investing.” 3. To read the Disclaimers, Disclosures, Investor Charter, Investor Complaints please visit our website abhayvarn.com

About the Author
CA Abhay Kumar (Also known as  CA Abhay Varn) is a qualified Chartered Accountant by profession and cleared CA at age 21. He is a SEBI Registered Research Analyst with Registration Number - INH300008465. He Possesses 8+ years of experience in the Stock Market Field and has also worked in Big CA firms.